NCI Project Targets Cancer Awareness in Asian-American Community

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 12 No 1
Volume 12
Issue 1

BETHESDA, Maryland-The National Cancer Institute (NCI) has launched a 5-year, $7.6 million project at seven leading cancer centers to address the disease among Asian Americans. Although Asian Americans have a relatively low overall risk, their cancer incidence is rising faster than that of any other racial or ethnic group in the United States.

BETHESDA, Maryland—The National Cancer Institute (NCI) has launched a 5-year, $7.6 million project at seven leading cancer centers to address the disease among Asian Americans. Although Asian Americans have a relatively low overall risk, their cancer incidence is rising faster than that of any other racial or ethnic group in the United States.

Asian Americans also suffer disproportionately from several forms of the disease, including liver, stomach, and cervical cancer.

The Asian-American community consists of more than 30 distinct ethnic groups and includes about 800 languages and dialects. The Asian-American Network for Cancer Awareness, Research, and Treatment (AANCART) will develop cancer awareness and prevention programs for specific subpopulations. It also aims to increase the number of Asian Americans participating in cancer clinical trials, train more Asian-American health care workers in community cancer prevention, and do research to reduce the cancer burden of this segment of the US population.

The University of California, Davis, Cancer Center will serve as headquarters for the project. Moon S. Chen, Jr., PhD, of UC-Davis, will be the principal investigator.

Other centers participating in the program are the Dana-Farber Cancer Institute, Boston; Herbert Irving Comprehensive Cancer Center, Columbia University, New York; Solove Cancer Research Center, Ohio State University, Columbus; Fred Hutchinson Cancer Research Center, Seattle; University of California, San Francisco, Comprehensive Cancer Center; and the UCLA Jonsson Comprehensive Cancer Center, Los Angeles. 

Recent Videos
Genetic consultation and next-generation sequencing can also complement treatment strategies for patients with pancreatic cancer.
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Related Content